One dose lowered blood fats by 75% on average in mice. Cellectis plans a China trial.

Cellectis (Nasdaq: CLLS) presented preclinical data for its .HEAL-101 gene therapy, showing 70% in vivo editing of human APOC3 and 76% triglyceride reduction in mice. The company plans a Phase 1 trial in China, with preliminary data expected in 2027. Cellectis aims to develop a one-time treatment for severe hypertriglyceridemia.

Original reporting
Published Oct 27, 2026, 7:15 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 7:18 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefTechnology
Primary signal
$CLLS
Bullish
high confidence
Mentioned
$CLLS
Relevance
8/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$CLLSBullishMed
01

Why it matters

The disclosed ~75% triglyceride reduction in mouse models represents a significant efficacy signal for .HEAL‑101, positioning Cellectis for a first‑in‑human trial in China in 2027.

02

Market read

First‑time disclosure of strong preclinical results could catalyze share price movement and influence investor sentiment toward gene‑editing biotech stocks.

03

What to watch

Regulatory timelines in China and potential competition from other APOC3 inhibitors could temper upside.

Relevance 8/10Novelty 8/10Timing: today

Background

Cellectis is a genome‑engineering company listed on Nasdaq (CLLS) and Euronext Growth (ALCLS). The announcement follows earlier preclinical data released in September 2026.

Company-level read

Ticker impact

$CLLSBullishHigh confidence
Context

Cellectis disclosed preclinical efficacy of its APOC3 base‑editing candidate .HEAL‑101, showing ~75% triglyceride reduction in mice and plans a Phase‑1 trial in China.

Expected impact

likely upward pressure as investors price in potential first‑in‑human data

Evidence & confidence

The data are a first‑time disclosure, materially improve the therapeutic outlook, and trigger speculative positioning before clinical initiation.

Market effects

Strengthens the broader gene‑editing and lipid‑lowering biotech sector, potentially benefitting peers developing similar in‑vivo base‑editing platforms.

May boost European biotech sentiment, especially French‑listed gene‑therapy firms, and attract Chinese investors interested in novel lipid‑lowering therapies.

Adds to the pipeline of innovative gene‑editing therapeutics, a theme of interest to global biotech funds.

Counterpoint

Preclinical success does not guarantee clinical efficacy; investors may remain cautious until human data are available.

Key entities

  • Cellectis

    Genome‑engineering firm developing .HEAL‑101 for severe hypertriglyceridemia.

  • .HEAL‑101

    TALE base‑editing candidate targeting APOC3, delivered via LNP‑mRNA.

Related articles

$CLLSMedAI 8/10

Cellectis Earnings Call Highlights In Vivo Editing Shift

Cellectis (CLLS) reported Q3 earnings, highlighting a shift to in vivo gene editing. Preclinical results for HEAL-101 and HEAL-201 showed promise, with HEAL-101 reducing APOC3 levels by 67% and triglycerides by 76% in mice. The company expects clinical data in 2027-2028. Revenue fell to $19.9M, but net income improved to a $5.2M gain. Cash runway extends into 2H 2028. Management also announced workforce reductions and discontinued legacy programs.

$CLLSMed

Cellectis SA (CLLS) (Q3 2026) Earnings Call Highlights: Strategic Shift to Gene

Cellectis SA (CLLS) discussed its strategic shift to gene editing during its Q3 2026 earnings call. Management highlighted the selection of APOC3 over ANGPTL3 for triglyceride reduction, with plans to start Phase 1 dosing by end-2027. The company reported $149M in cash as of September 30, 2026, with a runway into H2 2028. Revenue decreased to $19.9M from $67.4M YoY, while R&D expenses increased to $108.8M from $69.1M, driven by the AstraZeneca collaboration.

$CLLSMed

What Cellectis (CLLS) Said on Its Q3 Earnings Call

Cellectis (CLLS) reported Q3 earnings, highlighting HEAL-201's potential in reducing PCSK9 levels and plans for a Phase 1 trial. The company expects to cut global headcount by up to 70% in 2026-2027. Revenues fell to $19.9M from $67.4M YoY, while R&D expenses rose to $108.8M. Cash reserves were $149M as of Sept. 30, down from $211M at the end of 2025.

$CLLSMedAI 8/10

Cellectis Reports Third-Quarter 2026 Results and In Vivo Editing Data

Cellectis SA reported Q3 2026 results with $149M in cash, $19.9M revenue (down from $67.4M), and increased R&D expenses to $108.8M. Preclinical data showed promising results for .HEAL-101 and .HEAL-201. The company is shifting focus to in vivo gene editing, discontinuing lasme-cel and eti-cel programs. Analysts rate CLLS stock as Buy with $8.00 target, while TipRanks' AI rates it Neutral.